ArticleFrontiers in medicine2022
Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains: Multivariate Analysis of Clinical Efficacy and Optical Coherence Tomography Appearance.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of hemoporfin photodynamic therapy in treating port-wine stains in Chinese children: a systematic review and meta-analysis.Frontiers in pediatrics · 2024Pooled it
- Efficacy of photodynamic therapy in the treatment of port wine stains: A systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Noninvasive Diagnosis Revealed a Strong Therapeutic Response and Skin Barrier Changes in Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026Article
- The Diagnosis and Treatment Technology of Port-Wine Stain, and the Prospect of Future Treatment.Dermatology and therapy · 2026Review
- Computational modeling of oxygen dynamics in port-wine stain photodynamic therapy: treatment outcome optimization and pain management.Journal of biomedical optics · 2026Article
- Hemoporfin photodynamic therapy for port-wine stains in children: a prospective study.Frontiers in medicine · 2026Article
- Editorial: Photobiomodulation and phototherapy in skin diseases.Frontiers in medicine · 2023Article
- Hematoporphyrin Monomethyl Ether Photodynamic Therapy of Port Wine Stain: Narrative Review.Clinical, cosmetic and investigational dermatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemoporfin-mediated photodynamic therapy (HMME-PDT) is reported to be effective and safe for port-wine stains (PWS). However, its efficacy is influenced by several factors and there is no appropriate method to evaluate efficacy so far. Therefore, this study explored the clinical efficacy of HMME-PDT for PWS on the face and neck and the feasibility of evaluating treatment potency with optical coherence tomography (OCT). Methods: A total of 211 PWS patients subjected to HMME-PDT were recruited for study and correlations of therapeutic effect with treatment sessions, age, gender, lesion distribution and treatment history analyzed. OCT was utilized for quantitative analysis of PWS lesions of 36 selected patients before and after HMME-PDT. Results: The efficacy of two consecutive treatments was significantly higher than that of single treatment ( Conclusions: Our collective findings indicate that HMME-PDT therapy is effective and safe for PWS and support the utility of OCT in objective assessment of the efficacy of HMME-PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.